Search

Your search keyword '"de la Cerda, Francisco"' showing total 2 results
Start Over Author "de la Cerda, Francisco" Publisher elsevier
2 results on '"de la Cerda, Francisco"'

1. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

Author

Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Competitividad (España), Cavero, Teresa [0000-0001-5187-9906], Arjona, Emilia [0000-0002-0753-3657], Soto, Karina [0000-0002-6977-9361], Caravaca-Fontán, Fernando [0000-0002-5830-9663], Blasco, Miquel [0000-0003-0789-7992], Huerta, Ana [0000-0003-3342-7628], Fulladosa, Xavier [0000-0003-1974-9874], Ramos, Natalia [0000-0001-9832-326X], Morales-Ruiz, E. [0000-0002-5824-6973], Draibe, Juliana [0000-0002-2819-8560], Quintana, Luis F. [0000-0001-7582-8476], Barros, Xoana [0000-0001-9690-9769], Cao, Mercedes [0000-0002-8389-1800], Rodríguez de Córdoba, Santiago [0000-0001-6401-1874], Praga, Manuel [0000-0001-9270-1071], Cavero, Teresa, Arjona, Emilia, Soto, Karina, Caravaca-Fontán, Fernando, Rabasco, Cristina, Bravo, Luis, de la Cerda, Francisco, Martín, Nadia, Blasco, Miquel, Ávila, Ana, Huerta, Ana, Cabello-Chaves, Virginia, Jarque, Ana, Alcázar, Concepción, Fulladosa, Xavier, Carbayo, Javier, Anaya, Sara, Cobelo, Carmen, Ramos, Natalia, Iglesias, Elena, Baltar, José, Martínez-Gallardo, Rocío, Pérez, Lourdes, Morales-Ruiz, E., González, Roberto, Macía, Manuel, Draibe, Juliana, Pallardó, Luis, Quintana, Luis F., Espinosa, Mario, Barros, Xoana, Pereira, Fernando, Cao, Mercedes, Moreno, Juan Antonio, Rodríguez de Córdoba, Santiago, Praga, Manuel, Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Competitividad (España), Cavero, Teresa [0000-0001-5187-9906], Arjona, Emilia [0000-0002-0753-3657], Soto, Karina [0000-0002-6977-9361], Caravaca-Fontán, Fernando [0000-0002-5830-9663], Blasco, Miquel [0000-0003-0789-7992], Huerta, Ana [0000-0003-3342-7628], Fulladosa, Xavier [0000-0003-1974-9874], Ramos, Natalia [0000-0001-9832-326X], Morales-Ruiz, E. [0000-0002-5824-6973], Draibe, Juliana [0000-0002-2819-8560], Quintana, Luis F. [0000-0001-7582-8476], Barros, Xoana [0000-0001-9690-9769], Cao, Mercedes [0000-0002-8389-1800], Rodríguez de Córdoba, Santiago [0000-0001-6401-1874], Praga, Manuel [0000-0001-9270-1071], Cavero, Teresa, Arjona, Emilia, Soto, Karina, Caravaca-Fontán, Fernando, Rabasco, Cristina, Bravo, Luis, de la Cerda, Francisco, Martín, Nadia, Blasco, Miquel, Ávila, Ana, Huerta, Ana, Cabello-Chaves, Virginia, Jarque, Ana, Alcázar, Concepción, Fulladosa, Xavier, Carbayo, Javier, Anaya, Sara, Cobelo, Carmen, Ramos, Natalia, Iglesias, Elena, Baltar, José, Martínez-Gallardo, Rocío, Pérez, Lourdes, Morales-Ruiz, E., González, Roberto, Macía, Manuel, Draibe, Juliana, Pallardó, Luis, Quintana, Luis F., Espinosa, Mario, Barros, Xoana, Pereira, Fernando, Cao, Mercedes, Moreno, Juan Antonio, Rodríguez de Córdoba, Santiago, and Praga, Manuel

Abstract

Malignant hypertension is listed among the causes of secondary thrombotic microangiopathy (TMA), but pathogenic mutations in complement genes have been reported in patients with hypertension-induced TMA. Here we investigated the frequency and severity of hypertension in 55 patients with primary atypical hemolytic uremic syndrome (aHUS). A genetic analysis was performed in all patients, and funduscopic examination was performed in all the patients with Grades 2 and 3 hypertension. A cohort of 110 patients with malignant hypertension caused by diseases other than aHUS served as control. Thirty-six patients with aHUS presented Grade 2 or Grade 3 hypertension and funduscopic examination showed malignant hypertension in 19. Genetic abnormalities in complement were found in 19 patients (37% among patients with malignant hypertension). Plasmapheresis was performed in 46 patients and 26 received eculizumab. Renal and hematological responses were significantly lower after plasmapheresis (24%) than after eculizumab (81%). Renal survival was significantly higher in patients treated with eculizumab (85% at one, three and five years) compared to patients who did not receive this treatment (54%, 46% and 41%), respectively. Response to eculizumab was independent of hypertension severity and the presence of complement genetic abnormalities. Among patients with malignant hypertension caused by other diseases the prevalence of TMA was very low (5%). Thus, severe and malignant hypertension are common among patients with aHUS and eculizumab treatment leads to a higher renal survival when compared to plasmapheresis. However, TMA is uncommon among patients presenting with malignant hypertension caused by diseases other than aHUS.

Published
2019

2. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.

Author

Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, and Praga M

Subjects
Adult, Antibodies, Monoclonal, Humanized therapeutic use, Atypical Hemolytic Uremic Syndrome genetics, Atypical Hemolytic Uremic Syndrome therapy, Complement Inactivating Agents therapeutic use, Female, Humans, Hypertension, Malignant diagnosis, Hypertension, Malignant genetics, Hypertension, Malignant therapy, Incidence, Male, Middle Aged, Plasmapheresis, Retrospective Studies, Young Adult, Atypical Hemolytic Uremic Syndrome complications, Complement System Proteins genetics, Hypertension, Malignant epidemiology, Severity of Illness Index
Abstract

Malignant hypertension is listed among the causes of secondary thrombotic microangiopathy, but pathogenic mutations in complement genes have been reported in patients with hypertension-induced thrombotic microangiopathy. Here we investigated the frequency and severity of hypertension in 55 patients with primary atypical hemolytic uremic syndrome (aHUS). A genetic analysis was performed in all patients, and funduscopic examination was performed in all the patients with Grades 2 and 3 hypertension. A cohort of 110 patients with malignant hypertension caused by diseases other than aHUS served as control. Thirty-six patients with aHUS presented Grade 2 or Grade 3 hypertension and funduscopic examination showed malignant hypertension in 19. Genetic abnormalities in complement were found in 19 patients (37% among patients with malignant hypertension). Plasmapheresis was performed in 46 patients and 26 received eculizumab. Renal and hematological responses were significantly lower after plasmapheresis (24%) than after eculizumab (81%). Renal survival was significantly higher in patients treated with eculizumab (85% at one, three and five years) compared to patients who did not receive this treatment (54%, 46% and 41%), respectively. Response to eculizumab was independent of hypertension severity and the presence of complement genetic abnormalities. Among patients with malignant hypertension caused by other diseases the prevalence of thrombotic microangiopathy was very low (5%). Thus, severe and malignant hypertension are common among patients with aHUS and eculizumab treatment leads to a higher renal survival when compared to plasmapheresis. However, thrombotic microangiopathy is uncommon among patients presenting with malignant hypertension caused by diseases other than aHUS., (Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results